Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764474 · ClinicalTrials.gov registry record · Phase 1
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
A Phase 1 study, sponsored by Hutchmed.
- Terminated
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT04764474: Clinical Trial Phase 1 study, sponsored by Hutchmed.
NCT04764474 is a Phase 1 study that was terminated before completion, run by Hutchmed. The registered enrollment target is 46 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04764474, a Phase 1 study, was terminated before completion, sponsored by Hutchmed.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
Primary Outcome
RP2D determination took the following criteria under consideration: determination of maximum tolerated dose (MTD) achieved during the dose escalation part and assessment of safety, PK and pharmacodynamics (PD).
Interventions
- DRUG HMPL-306
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 1 |
Why NCT04764474 stopped before completion
NCT04764474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 1 intervention - of which HMPL-306 is the first listed.
NCT04764474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04764474 about?
NCT04764474 is a clinical study titled "A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH". An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
What is the current status of trial NCT04764474?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2021-04-12. Estimated completion is 2025-01-15.
What interventions are being tested in trial NCT04764474?
The interventions under investigation include: HMPL-306 (DRUG).
Who is sponsoring clinical trial NCT04764474?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04764474's enrollment target sits among peer trials
46 1058th of 2000 higher than 935 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI